![](/img/cover-not-exists.png)
8517 Phase I results from an open-label, randomized, controlled, phase I/II study (ADVANTAGE) to evaluate the combination of different cilengitide regimens with cisplatin, 5-FU, and cetuximab in patients with recurrent/metastatic squamous cell cancer of the head and neck (SCCHN)
Brümmendorf, T., Guigay, J., Mesía, R., Trigo, J., Keilholz, U., Dittrich, C., Kerber, A., Picard, M., Vermorken, J.Volume:
7
Language:
english
Journal:
European Journal of Cancer Supplements
DOI:
10.1016/S1359-6349(09)71608-8
Date:
September, 2009
File:
PDF, 72 KB
english, 2009